EAN 2026 | Combining device-aided therapies to improve outcomes for patients with Parkinson’s disease
Francesca Morgante, MD, PhD, St George’s University of London, London, United Kingdom, discusses the future role of combination therapies in Parkinson’s disease. She explains how apomorphine infusion can be used alone or alongside other device-aided therapies, including deep brain stimulation, to optimize symptom control, reduce medication burden, and improve quality of life. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Apomorphine infusion and device-aided therapies have a huge impact on the quality of life of people with Parkinson’s disease. These are improvements that sometimes are not even captured by common outcome measures. People report more confidence and sense of well-being. They’re back to living their lives. They’re back to function socially. That is one of the most important outcomes for any person with a neurological disorder...
Apomorphine infusion and device-aided therapies have a huge impact on the quality of life of people with Parkinson’s disease. These are improvements that sometimes are not even captured by common outcome measures. People report more confidence and sense of well-being. They’re back to living their lives. They’re back to function socially. That is one of the most important outcomes for any person with a neurological disorder. Apomorphine infusion can be used in different moments in the lifetime of a person with Parkinson’s disease. It can be used to treat wearing-off that is affecting functioning in daily life. It can also be used as a bridge therapy for other device-aided therapies, such as deep brain stimulation and can also be combined with other device therapies, such as deep brain stimulation, in people that, for example, have a long time duration of this treatment and they require infusion therapy to optimize the residual levodopa that is needed in combination. There is now evidence of combining different device-aided therapies because, ultimately, what we want, we want to determine good control of symptoms during the daytime and nightime, with minimal psychiatric complications, and also making sure that patients are compliant with medication intake. And infusion therapies allow to realize that because patients they don’t need to be reminded to take tablets several of times tablets during the day.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
